ReviewEpigenetics & chromatin2026
All hands on DEK: structural insights into a unique histone modifier and chromatin remodeler.
Review in Epigenetics & chromatin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
DEK is a chromatin-associated, DNA-binding protein with unique properties that place it in its own protein class. First discovered in 1992 as a fusion protein in acute myeloid leukemia, DEK gained further attention in the mid-2000s as a growing number of studies identified its connections to chromatin architecture and subsequent impact on pathologies such as cancer and autoimmune diseases. Current evidence indicates that DEK can alter the topology of nucleic acids in a variety of biological processes, including DNA replication, DNA repair, chromatin organization, epigenetic modification, transcription, and mRNA splicing. Interestingly, DEK is highly evolutionarily conserved among higher eukaryotes, and this, combined with its involvement in such a diverse array of processes, highlights its biological significance. Interest in DEK is further driven by its status as a potent oncogene, as it is transcriptionally upregulated in most solid tumors tested to date, with high DEK expression correlating with poor survival and more aggressive tumors. Recently, advances in cryogenic electron microscopy have made it possible to visualize the structural basis of DEK-nucleosome interactions, providing concrete mechanistic insights into how DEK influences gene regulation and transcription. These findings clarify prior observations and open new avenues for exploring the biological and clinical relevance of DEK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.